Uses of fructosine and deoxyfructosine in hair growth, hair care, hair strengthening and hair loss prevention
By using cosmetics or drugs with fructosine and deoxyfructosine as active ingredients, the problems of slow effectiveness and large side effects of existing hair loss treatments have been solved, achieving the effects of promoting hair growth and preventing hair loss.
Patent Information
- Application Number
- CN202410840532.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-06-26
- Publication Date
- 2026-11-10
- Estimated Expiration
- 2044-06-26
AI Technical Summary
Existing hair loss treatments, such as minoxidil and finasteride, have problems such as slow effectiveness and many adverse reactions. Hair growth cosmetics are not very effective for moderate to severe hair loss, and hair transplantation cannot change the progression of the disease and is expensive. There is an urgent need to develop new products to promote hair growth and prevent hair loss.
Using fructosamine and deoxyfructosamine as active ingredients, cosmetics or drugs are prepared for hair growth, hair care, hair strengthening and hair loss prevention. By accelerating the growth of hair follicle cells, promoting the transformation from the resting phase to the growth phase, improving the condition of hair follicles, and preventing hair follicle damage and degeneration.
Fructose and deoxyfructose significantly promote hair growth, improve hair quantity and quality, prevent hair loss, and have few side effects, providing effective relief for hair loss.
Smart Images

Figure CN118845781B_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of biomedicine and cosmetics technology, and relates to the application of two compounds, fructosine (FZ) and deoxyfructosine (DOF), specifically the use of fructosine and deoxyfructosine in hair growth, hair care, hair strengthening and hair loss prevention. Background Technology
[0002] In recent years, more and more people have been suffering from hair loss. The phenomenon is also increasingly affecting younger people, with 60% experiencing hair loss by the age of 25. Although clinical data shows that the number of men with pathological hair loss is far greater than that of women, women make up a higher percentage of the population troubled by hair loss. In terms of age, the group most concerned about hair loss is young people born in the 1990s and 2000s.
[0003] Hair loss refers to the phenomenon of hair falling out. Normally shed hairs are in the telogen (resting) and catagen (transitional) phases. Because the number of hairs entering the telogen phase and those newly entering the anagen (growth) phase is constantly in dynamic equilibrium, a normal amount of hair is maintained; this is normal physiological hair loss. Pathological hair loss refers to abnormal or excessive hair loss, which has many causes. Common clinical hair loss diseases include androgenetic alopecia, alopecia areata, syphilitic alopecia, cicatricial alopecia, telogen effluvium, and pseudoalopecia areata, among which 90% of hair loss cases are androgenetic alopecia. Androgenetic alopecia (AGA) is the most common type of hair loss, a progressive hair follicle miniaturization disease that begins in puberty or late puberty. Essentially, testosterone in the body is converted into dihydrotestosterone (DHT) by 5α-reductase in the hair follicle cells of the scalp. DHT attacks the hair follicles, causing them to prematurely enter the telogen phase and eventually shrink and fall out. The prevalence of this disease varies significantly among different races, with a higher incidence in Caucasians. In my country, the prevalence rate is approximately 21.3% in men and approximately 6.0% in women.
[0004] Currently, there are three main treatments for hair loss: topical medications, oral medications, and hair transplantation. Minoxidil is a popular first-line topical treatment. However, minoxidil's average onset time is 6-9 months, and some patients experience telogen effluvium (resting phase hair loss) and adverse reactions. Oral minoxidil has also been considered clinically effective in recent years, with some literature reporting its effectiveness in treating androgenetic alopecia and telogen effluvium. However, this drug can cause contact dermatitis, facial hirsutism, and other adverse reactions. Oral medications include finasteride, dutasteride, and spironolactone. The first two are 5α-reductase inhibitors and are effective in improving hair loss, but both can cause sexual dysfunction. Spironolactone is suitable for treating female AGA, but it has a long onset time, many adverse reactions, and requires regular monitoring of blood potassium levels during treatment. Hair transplantation involves using follicular unit extraction and follicular unit scalp strip cutting techniques to redistribute existing hair from the donor area to the recipient area. This procedure does not promote hair regrowth. During the surgery, the surgeon should maintain the anatomical integrity of the hair follicles and strive for a natural and aesthetically pleasing hair distribution. However, since AGA (Advanced Geriatric Alopecia Areata) is a lifelong process, hair transplantation will not alter its progression. Continued use of medications to treat AGA is necessary, and the surviving hair in non-transplanted areas only becomes apparent 6-9 months post-surgery. Furthermore, this method has disadvantages such as high cost and the inability to alleviate disease progression.
[0005] Drug therapy and hair transplantation are the main means of dealing with mild, moderate and severe hair loss, respectively, which have solved the hair loss problems faced by some patients. However, many patients still cannot achieve effective relief due to issues such as the limited effectiveness of existing drugs and various adverse reactions caused by treatment.
[0006] Besides the treatments mentioned above, hair growth cosmetics are also an effective product for preventing hair loss, protecting hair, and strengthening hair. These cosmetics are generally formulated with traditional Chinese medicine ingredients to promote hair growth and nourish hair follicles. It's worth noting that these products have relatively few side effects. Common active ingredients include Polygonum multiflorum, black sesame, Astragalus membranaceus, dried ginger, Plantago asiatica, and ginseng. These traditional Chinese medicine active ingredients can stimulate scalp cell activity, inhibit bacteria and inflammation, suppress androgens, prevent hair loss, and promote scalp cell metabolism. Furthermore, many natural herbs, such as Eclipta prostrata, Platycladus orientalis, Helichrysum fusiforme, and Cornflower, have been identified as having 5α-reductase inhibitory activity. Hair growth cosmetics usually have fewer side effects and are used by patients in the early stages of hair loss or when first symptoms appear to alleviate hair loss and nourish hair. However, the effect is less pronounced for patients with moderate to severe hair loss, and it may not achieve a therapeutic effect.
[0007] With hair loss becoming increasingly serious, the development of new hair growth-promoting drugs and cosmetic products remains an urgent need.
[0008] Fructosazine (FZ), chemically named 1,1'-(2,5-pyrazine)-bis-1,2,3,4-butanetetrazol, and deoxyfructosazine (DOF), chemically named 2-[(1R,2S,3R)-1,2,3,4-hydroxybutyl]-5-[(2S,3R)-2,3,4-trihydroxybutyl]pyrazine, belong to the polyhydroxyalkylpyrazine (PHAP) family. They were initially discovered, isolated, and their structures were identified in baked foods. (Identification of novel non-volatile pyrazines in commercial caramel colors, Developments in Food Science, 1986. Isolation and identification of polyhydroxyalkylpyrazines in soy sauce, Nippon Shokuhin Kogyo Gakkaishi, 1990. Effect of roasting time and temperature on the generation of nonvolatile (polyhydroxyalkyl)pyrazine compounds in peanuts, as determined by high-performance liquid chromatography, Journal of Agricultural and Food Chemistry, 1996.) These compounds are used as flavoring agents in the food industry due to their unique and appealing aroma (Natural colorants for food and nutritional supplements, CRC Press, 2002); and are used to enhance or alter the flavor of tobacco smoke due to their low odor threshold (Deoxyfructazine's flavor-enhancing effect in cigarettes, Tobacco Technology, 2008). These compounds have inhibitory activity against interleukins and may help prevent pathological cartilage degradation and other inflammatory diseases.(2,5-Deoxyfructosazine,a D-glucosamine derivative,inhibits T-cell interleukin-2production better than D-glucosamine,Carbohydrate Research,2007.2,5-bis(tetrahydroxybutyl)pyrazines for the treatment of osteoarthritis andrheumatoid arthritis: EP1704862A1, 2006.) has antimicrobial activity (Fructosazine, apolyhydroxyalkylpyrazine with antimicrobial activity: mechanism of inhibition against extremely heat resistant Escherichia coli. Journal of Agricultural and Food Chemistry, 2016) and can improve DNA fragmentation (Iron(Fe. 2+ (Catalyzed glucosamine browning at 50℃: identification and quantification of major flavor compounds for antibacterial activity, Journal of Agricultural and Food Chemistry, 2016), exhibits inhibitory activity against α-glucosidase (Chemical constituents in leaves of Morus atropurpurea and their α-glucosidase activity, Traditional Chinese Medicine, 2013), and shows good anti-aging activity against both pre-senescent and mid-senescent cells (Synthesis and anti-aging evaluation of fructosamine, Fine Chemicals, 2021). In summary, fructosamine and deoxyfructosamine are a class of compounds with diverse biological activities, but their effects on hair growth and hair strengthening have not yet been reported. Summary of the Invention
[0009] This invention studies the hair growth, hair nourishment, hair strengthening and hair loss prevention effects of FZ and DOF, and provides their application as novel hair growth and hair loss treatment drugs or active ingredients in cosmetics.
[0010] The technical solution of this invention:
[0011] Applications of fructosine and deoxyfructosine in the preparation of products for hair growth, hair care, hair strengthening and hair loss prevention.
[0012] The product's active ingredients are fructosamine and / or deoxyfructosamine. The product's functions include at least one of the following: a) improving hair smoothness; b) increasing hair volume; c) promoting hair growth; d) reversing hair follicle degeneration; the product is a pharmaceutical or cosmetic formulation.
[0013] When the product is a cosmetic formulation, fructosine and / or deoxyfructosine are used independently or in combination as active cosmetic ingredients; the total amount of fructosine and / or deoxyfructosine is based on the total weight of the cosmetic formulation, with a mass fraction of 0.1% to 99.9%. The product contains deoxyfructosine and / or fructosine as well as a cosmetically acceptable carrier. The applicable type of cosmetically acceptable carrier depends on the form of the cosmetic formulation. The cosmetic formulation can be in any suitable form without specific limitations; the cosmetic formulation is in the form of a topical solution, lotion, cream, gel, ointment, foam, spray, shampoo, or other skincare or cosmetic product, which can be applied by application or spraying onto the hair and scalp.
[0014] When the product is a drug, it is mainly composed of fructosine and / or deoxyfructosine, their carriers, and pharmaceutically additive excipients.
[0015] The drug also contains a combination drug formulation, preferably minoxidil.
[0016] The excipients include one or more of the following: solvent, cosolvent, emulsifier, colorant, diluent, excipient, filler, binder, wetting agent, disintegrant, osmotic pressure regulator, stabilizer, flavoring agent, preservative, penetration enhancer, pH adjuster, absorption enhancer, surfactant, foaming agent, adsorbent carrier, and lubricant.
[0017] The drug is a topical preparation.
[0018] The beneficial effects of this invention are:
[0019] In this invention, fructosine and / or deoxyfructosine can accelerate hair follicle cell growth and promote the transition from the resting phase to the growth phase; fructosine and / or deoxyfructosine can improve the condition of the hair shaft and cuticle; fructosine and / or deoxyfructosine can improve the condition of the skin hair follicles, making them arranged tightly and orderly; fructosine and / or deoxyfructosine can prevent hair loss caused by hair follicle damage and hair follicle degeneration.
[0020] Using a mouse hair removal model, tests revealed that fructosamine and deoxyfructosamine promote the transition of resting hair follicles to the anagen phase, increasing hair length and weight, and producing shiny, black new hair. In a mouse model where imiquimod was applied after hair removal to inhibit hair growth and hair loss, tests showed that both fructosamine and deoxyfructosamine could alleviate the hair growth inhibition and hair loss caused by imiquimod. In a rat model where fructosamine and deoxyfructosamine were continuously applied after shaving, tests showed that fructosamine and deoxyfructosamine can promote hair growth and follicle development, resulting in a tight and orderly arrangement of hair follicles in the skin. Continuous application of low-concentration fructosamine aqueous solution to individuals with hair loss showed effectiveness. The fructosamine and deoxyfructosamine of this invention have significant effects on promoting hair growth, nourishing hair, strengthening hair, and preventing hair loss in the process of hair loss prevention and treatment, providing a strong basis for further research and development of this type of compound. Attached Figure Description
[0021] Figure 1 To investigate the hair growth on the backs of mice in different groups on days 0, 6, 10, and 14 during step one.
[0022] Figure 2 A bar chart comparing the average hair length for each group: ***P<0.001, ****P<0.0001 compared to the model group. The experimental results indicate that high doses of DOF are beneficial for hair growth.
[0023] Figure 3 A bar chart comparing the average gross weight of each group; compared with the model group, *P<0.05, ***P<0.001. The results show that both low-dose FZ and high-dose DOF are beneficial for hair regrowth, with low-dose FZ showing a more significant effect.
[0024] Figure 4 The image shows the hair growth on the backs of different mouse classes on day 0, day 10, and the last day during step two.
[0025] Figure 5 Microscopic images of rat skin sections under drug-induced and untreated conditions.
[0026] Figure 6 Comparison photos of volunteers with hair loss treated with low-concentration fructose azithromycin spray, where (a) is before spraying for volunteer 1; (b) is one month after spraying for volunteer 1; (c) is before spraying for volunteer 2; and (d) is one month after spraying for volunteer 2. Detailed Implementation
[0027] The present invention will be further illustrated below with reference to the accompanying drawings and embodiments, but this is not intended to limit the invention. Specific materials used in the embodiments of the present invention and their sources are provided below. However, it should be understood that these are merely exemplary and not intended to limit the invention. Materials of the same or similar type, model, quality, properties, or functions as the reagents and instruments described below can be used to implement the present invention. Unless otherwise specified, the experimental methods used in the following embodiments are conventional methods. The materials and reagents used in the following embodiments, except for fructosamine and deoxyfructosamine which are prepared in the laboratory, are all commercially available.
[0028] Experimental steps of this invention:
[0029] Step 1: Experimental study on the effects of fructosamine and deoxyfructosamine on hair growth and the appropriate medicinal concentration.
[0030] Six cages of mice, eight mice per cage, were used to establish a hair removal model by taking small squares of appropriate area from the middle of the backs of all mice. One cage was used as a group, with one cage not treated with the drug as the control group; the other five cages were evenly treated with different concentrations of fructosamine solution, deoxyfructosamine solution, or minoxidil on their backs once a day for three consecutive weeks. The hair growth on the backs of the mice was recorded and observed daily.
[0031] After the experiment, tweezers were used to collect hair from the back of each mouse. A suitable amount of hair was taken from each mouse for measurement, and the average value was taken to represent the effect of the drug on the hair length of the mice. Then, the newly grown hair on the back of the mice was shaved, and the same area was selected. All of the hair was then shaved off and weighed. The average value of each group was taken, and the data of hair length and hair weight of mice in each group were compared.
[0032] Step 2: Investigate the effects of fructosamine and deoxyfructosamine in preventing hair loss at appropriate drug concentrations.
[0033] Based on the previously explored concentrations, experiments were conducted. All mice were ear-tagged, and after removing hair from their backs and using sodium sulfide for hair removal, imiquimod was applied to establish the hair growth model. Control groups, low-concentration fructosamine groups, high-concentration deoxyfructosamine groups, and minoxidil groups were established. On Mondays, Wednesdays, Fridays, and Sundays each week, mice in the control group and those receiving the drug were uniformly applied imiquimod once. During this period, photos were taken daily to record and observe hair growth, comparing the degree of reduction in hair follicle inhibition.
[0034] Step 3: The effects of the two drugs were compared by staining and microscopic observation of rat skin sections.
[0035] SD rats were randomly divided into two groups (fructosamine group and deoxyfructosamine group). Two skin patches were selected from the back of each rat, and the hair in the sampling area was carefully shaved using a power epilator. One skin patch served as a negative control, while the other patch was treated with the drug solution. A certain concentration of fructosamine aqueous solution and deoxyfructosamine aqueous solution were applied to the hair-treated rats daily for one experimental cycle (21 days). During the application process, hair growth in the control and treated areas was compared. After 21 days, the rats were sacrificed, and the skin on their backs was dissected with a scalpel. The required skin samples were removed with surgical scissors, fixed with a sample clip, and then fixed with formaldehyde solution. Subsequently, paraffin sections were prepared from the samples and stained with hematoxylin and eosin (HE).
[0036] Example 1:
[0037] 1. Method
[0038] Six cages of ten-week-old female C57BL / 6 mice, eight mice per cage, were used. A 1*2cm square was cut from the middle of the back of each mouse and the hair was shaved. Each cage was a group, with one cage as the control group and the other five cages as the treatment groups: 0.25mg / mL FZ low concentration group, 0.5mg / mL FZ high concentration group, 0.24mg / mL DOF low concentration group, 0.48mg / mL DOF high concentration group, and minoxidil group. The treatment was applied evenly to the back of the mice once a day at the same time for three consecutive weeks. Photos were taken daily to record and observe the hair growth on the back of the mice.
[0039] After the experiment, tweezers were used to collect newly grown hair from the shaved back of each mouse. Twenty of the longest hairs from each mouse were measured, and the average value was taken to represent the effect of the drug on mouse hair length. Then, all the newly grown hair from the shaved back of the mice was shaved off again and weighed, with the average value for each group being taken. The hair length and weight data of each group were then compared.
[0040] 2. Data Analysis:
[0041] like Figure 1 , Figure 2 and Figure 3 As shown, fructosine and deoxyfructosine promote hair growth in mice, and the effects of low-concentration fructosine solution and high-concentration deoxyfructosine solution are relatively more pronounced. Figure 2In the model group, the hair length was 7.58±1.24 mm; in the low FZ group, it was 7.73±1.54 mm; in the high FZ group, it was 7.451±1.15 mm; in the low DOF group, it was 7.74±1.27 mm; in the high DOF group, it was 8.36±1.36 mm; and in the minoxidil group, it was 7.73±1.19 mm. The mean hair lengths of the low FZ and low DOF groups were similar to those of the minoxidil group, but greater than those of the model group. The high DOF group showed significantly greater hair lengths than the other five groups (P<0.001). Figure 3 In the study, the gross weight of the model group was 9.864±0.66 mg, the gross weight of the normal group was 15.09±2.68 mg, the gross weight of the low FZ group was 14.58±2.76 mg, the gross weight of the high FZ group was 11.06±1.483 mg, the gross weight of the low DOF group was 11.75±0.62 mg, the gross weight of the high DOF group was 12.6±0.76 mg, and the gross weight of the minoxidil group was 10.85±0.93 mg. The gross weight of all treatment groups was greater than that of the model group and the positive control minoxidil group, but less than that of the normal group; the gross weight of the low FZ group was close to that of the normal group, and there was a significant difference compared with the model group (P<0.001).
[0042] Example 2:
[0043] 1. Method
[0044] Imiquimod was used to establish a hair loss model. Sixteen female C57BL / 6 mice were used. The hair on their backs (1*2 cm) was shaved and removed with sodium sulfide solution. The mice were then divided into two cages. One cage was used to investigate the effect of imiquimod on preventing hair loss. Two mice in this cage were treated with 0.25 mg / mL fructosamine solution once daily, two were treated with 0.48 mg / mL deoxyfructosamine solution, two were treated with minoxidil tincture, and two were not treated with any medication. Simultaneously, on Mondays, Wednesdays, Fridays, and Sundays, the mice in this cage treated with imiquimod were additionally and evenly treated. The other cage was designated the model group, with 8 mice treated with imiquimod at the same time each week, and no other treatments were given at other times. Daily photographs were taken to record changes in the model area.
[0045] 2. Results Analysis:
[0046] like Figure 4 As shown, compared to the model group, all treatment groups exhibited effects in promoting hair growth and preventing hair growth inhibition caused by imiquimod. The figures show that the skin of the model group remained pink, while hair growth was observed in the fructosamine, deoxyfructosamine, and minoxidil groups.
[0047] Example 3:
[0048] 1. Method
[0049] SD rats were randomly divided into two groups (fructosamine group and deoxyfructosamine group). Two 2cm × 2cm skin patches were selected from the back of each rat. Hair was carefully shaved from the sampling sites using a power epilator. One patch served as a negative control, while the other patch was treated with the drug solution. Care was taken to avoid damaging the skin during shaving, as this could affect subsequent experimental results. If hair grew back during the treatment process, it was shaved off with a power epilator to ensure effective drug application to the rats. The rats were treated daily with 100μL of 0.25mg / mL fructosamine aqueous solution (containing 10% propylene glycol) and 100μL of 0.24mg / mL deoxyfructosamine aqueous solution (containing 10% propylene glycol) for 3 consecutive weeks. After application, rats were euthanized by ether inhalation, and the skin on the back of the rats was peeled off with a scalpel. The required skin samples were taken with surgical scissors, and the skin was fixed with a sample clip to prevent it from curling and affecting the subsequent staining results. The samples were then fixed in 4% paraformaldehyde solution. Paraffin sections were prepared from the samples and stained with hematoxylin and eosin (HE).
[0050] 2. Results Analysis:
[0051] HE staining can reflect the basic histological morphology and structural characteristics of the skin. For example... Figure 5 As shown, the skin treated with fructosine and deoxyfructosine did not show any adverse reactions such as redness, swelling, or inflammatory infiltration after drug treatment, compared with the untreated skin of the same mouse. After drug treatment, the epidermis of the rats was continuous and compact. Microscopic observation of the sections revealed that the hair follicles were neatly and tightly arranged, and the cells in the hair follicle area were darker in color and more actively dividing, indicating that the drug has a nourishing effect on hair follicle development.
Claims
1. Application of fructosine and deoxyfructosine in the preparation of products for hair growth or hair care.
2. The application according to claim 1, characterized in that, The active ingredients of the product are fructosine and / or deoxyfructosine; the functions of the product include at least one of the following: a) improving hair smoothness; b) promoting hair growth; c) reversing hair follicle degeneration; the product is a pharmaceutical or cosmetic formulation.
3. The application according to claim 2, characterized in that, When the product is a cosmetic formulation, fructosine and / or deoxyfructosine are used independently or in combination as active cosmetic ingredients; the total amount of fructosine and / or deoxyfructosine is based on the total weight of the cosmetic formulation, with a mass fraction of 0.1% to 99.9%.
4. The application according to claim 3, characterized in that, The product contains deoxyfructazine and / or fructazine as well as a cosmetic acceptability carrier; the applicable types of cosmetic acceptability carriers depend on the form of the cosmetic formulation.
5. The application according to claim 3 or 4, characterized in that, The cosmetic formulation is in the form of a solution, lotion, cream, gel, ointment, foam, or spray for topical use, applied by smearing or spraying onto the hair and scalp.
6. The application according to claim 2, characterized in that, When the product is a drug, it is mainly composed of fructosine and / or deoxyfructosine, their carriers, and pharmaceutically additive excipients.
7. The application according to claim 6, characterized in that, The excipients include one or more of the following: solvent, cosolvent, colorant, diluent, excipient, filler, binder, wetting agent, disintegrant, osmotic pressure regulator, stabilizer, flavoring agent, preservative, penetration enhancer, pH adjuster, absorption enhancer, surfactant, adsorbent carrier, and lubricant.
8. The application according to claim 7, characterized in that, The surfactant is a foaming agent or an emulsifier.
9. The application according to claim 2, 6, or 7, characterized in that, The drug also contains drug formulations that can be used in combination.
10. The application according to claim 9, characterized in that, The drug formulation that can be used in combination is minoxidil.
11. The application according to claim 2, 6, or 7, characterized in that, The drug is a topical preparation.
Citation Information
Patent Citations
Preparation method and application of fructosazine
CN112679443A
